Australia markets closed
  • ALL ORDS

    6,943.00
    -57.60 (-0.82%)
     
  • ASX 200

    6,710.80
    -49.90 (-0.74%)
     
  • AUD/USD

    0.7683
    -0.0036 (-0.47%)
     
  • OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD

    1,698.20
    -2.50 (-0.15%)
     
  • BTC-AUD

    63,575.39
    +578.66 (+0.92%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • AUD/EUR

    0.6446
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0718
    -0.0018 (-0.17%)
     
  • NZX 50

    12,180.25
    -44.25 (-0.36%)
     
  • NASDAQ

    12,668.51
    +204.51 (+1.64%)
     
  • FTSE

    6,630.52
    -20.36 (-0.31%)
     
  • Dow Jones

    31,496.30
    +572.16 (+1.85%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • Hang Seng

    29,098.29
    -138.50 (-0.47%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     

General Dynamics (GD) Arm Wins $695M US Army Europe Contract

Zacks Equity Research
·3-min read

General Dynamics GD announced that its unit General Dynamics Information Technology (GDIT) has received a contract from The General Services Administration to provide Enterprise Mission Information Technology Services. The deal is valued at $695 million.

Details

Per the terms of the deal, the subsidiary’s services will include delivering enterprise information technology, communications and mission command support services to the United States Army Europe (USAREUR) headquarters, US North Atlantic Treaty Organization operations, and other forward deployed Department of Defense organizations and Regionally Aligned Forces in Europe. The task order will span over a five-year period comprising a three-month transition, one-year base period and four one-year options.

Previously, GDIT was awarded the Theater Mission Command Contract (TMCC) II task order in 2016. Backed by this order, the unit will deliver technical expertise in cybersecurity solutions to further optimize the critical mission command networks and systems, thus enabling USAREUR operations to advance its global mission.

Strong Demand

During the third quarter of 2020, General Dynamics witnessed strong order growth, in line with its usual trend. This, in turn, boosted its backlog, which grew 21% year over year to $81.5 billion. Such impressive backlog trends indicate solid demand for the company’s products, thereby bolstering its revenue generation prospects significantly.

On Dec 23, 2020, General Dynamics’ business unit Land Systems was awarded a $4.6-billion fixed-price-incentive contract to produce M1A2 SEPv3 Abrams main battle tanks for the U.S. Army.

Earlier in November, GDIT was awarded a contract by the Department of Health and Human Services Centers for Medicare and Medicaid Services to provide cloud services and software tools. Also, in the same month, another unit of the company, General Dynamics Electric Boat, was awarded a $9.5-billion contract by the U.S. Navy for construction and trial of the lead and second ships of the Columbia class as well as for associated design and engineering support.

Zacks Rank & Price Performance

The stock currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of General Dynamics have gained 2.3% in the past month against the industry’s decline of 1.1%.

Stocks to Consider

A few better-ranked stocks from the same space are Leidos Holdings, Inc. LDOS, Transdigm Group Incorporated TDG and Ducommun Incorporated DCO, all carrying a Zacks Rank#2 (Buy), at present.

Leidos Holdings has a long-term (three-five years) earnings growth rate of 10.84%. It delivered an earnings surprise of 17.57%, on average, in the last four quarters.

Transdigm Group delivered an earnings surprise of 37.24%, on average, in the last four quarters. The company has a long-term earnings growth rate of 4.03%.

Ducommun delivered an earnings surprise of 66.73%, on average, in the trailing four quarters. The Zacks Consensus Estimate for 2021 earnings has moved 1.1% north in the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
General Dynamics Corporation (GD) : Free Stock Analysis Report
 
Transdigm Group Incorporated (TDG) : Free Stock Analysis Report
 
Ducommun Incorporated (DCO) : Free Stock Analysis Report
 
Leidos Holdings, Inc. (LDOS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.